API-192 / Appia Bio, Gilead - LARVOL DELTA

Preclinical development of API-192: An engineered CAR-NKT allogeneic cell therapy targeting CD19 and CD20 for the treatment of B-cell malignancies (AACR 2024) - "In an autonomous growth assay, API-192 expands at a low level and subsequently contracts, suggesting a lack of dysregulated growth. Collectively, these results demonstrate the favorable manufacturability, potency, and safety of API-192 and its potential as a novel allogeneic therapy."

Late-breaking abstract • Preclinical • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD34 • IFNG • IL15 • TRB

API-192, an Allogeneic CD19/20 CAR-NKT Cell Product Derived from Cord Blood CD34+ HSPCs for the Treatment of B-Cell Malignancies (ASH 2023) - "Compared to conventional CAR-T cells, API-192 also secretes minimal levels of IFN-γ in response to co-culture with healthy donor peripheral blood mononuclear cells, consistent with the expression of a non-HLA restricted TCR and low GvH risk. These results demonstrate the feasibility, potency, and potential safety of API-192, warranting further development as a novel allogeneic therapy."

IO biomarker • Graft versus Host Disease • Hematological Malignancies • Immunology • Oncology • CD34 • CD8 • IFNG • IL15

Appia Bio to Present Data on API-192 at the 65th American Society for Hematology Annual Meeting and Exposition (PRNewswire) - "Appia Bio, Inc...today announced that it will present preclinical data on API-192, a first-in-class CAR-NKT allogeneic cell therapy for the treatment of a broad array of B-cell mediated malignancies including non-Hodgkin lymphoma, one of the most common cancers in the U.S...These data will be delivered in a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023 in San Diego, CA."

Preclinical • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology